Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $15.83.

Several research firms have recently commented on OCUL. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Ocular Therapeutix in a research report on Friday, June 14th. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Friday, June 21st. StockNews.com lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. TD Cowen lowered Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 21st. Finally, JMP Securities reduced their target price on Ocular Therapeutix from $24.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th.

Institutional Trading of Ocular Therapeutix

Several large investors have recently added to or reduced their stakes in OCUL. SG Americas Securities LLC grew its stake in Ocular Therapeutix by 60.5% during the 4th quarter. SG Americas Securities LLC now owns 19,646 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 7,404 shares during the last quarter. Raymond James & Associates boosted its stake in shares of Ocular Therapeutix by 7.0% in the fourth quarter. Raymond James & Associates now owns 129,012 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 8,451 shares during the last quarter. Relyea Zuckerberg Hanson LLC purchased a new stake in shares of Ocular Therapeutix in the fourth quarter worth about $78,000. Deltec Asset Management LLC boosted its stake in shares of Ocular Therapeutix by 18.5% in the fourth quarter. Deltec Asset Management LLC now owns 2,443,607 shares of the biopharmaceutical company’s stock worth $10,898,000 after buying an additional 381,810 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Ocular Therapeutix by 350.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,192 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 7,152 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Price Performance

OCUL opened at $8.46 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 21.39 and a quick ratio of 21.29. Ocular Therapeutix has a 12 month low of $2.00 and a 12 month high of $11.31. The stock has a fifty day moving average price of $6.56 and a 200-day moving average price of $6.90.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $14.77 million during the quarter, compared to the consensus estimate of $15.43 million. Ocular Therapeutix had a negative return on equity of 76.64% and a negative net margin of 192.61%. As a group, equities research analysts expect that Ocular Therapeutix will post -0.98 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.